Uninterrupted treatment with dabigatran, a non-vitamin K antagonist oral anticoagulant (NOACs), before, during and after ablation to treat atrial fibrillation significantly reduced the incidence of major bleeding events compared with uninterrupted use of the more established anticoagulant warfarin, according to research presented at the American College of Cardiology’s 66th Annual Scientific Session.
Patients experiencing a major heart attack often have more than one clogged artery, but under current guidelines doctors typically only clear the blockage responsible for the heart attack. Assessing and, when warranted, treating the additional blockages can improve patient outcomes and reduce the need for subsequent invasive procedures, according to research presented at the American College of Cardiology’s 66th Annual Scientific Session.
In the first randomized, double-blinded trial of an online behavioral intervention for high blood pressure, participants in web-based lifestyle counseling reduced their systolic blood pressure by 10 mmHg, compared with a 6 mmHg reduction for those taking part in a web-based control intervention, a statistically significant difference. The research was presented at the American College of Cardiology’s 66th Annual Scientific Session.
A new class of cholesterol-lowering drug has been found to help patients cut their risk of cardiovascular disease, stroke and heart attack.
In a trial of more than 27,000 patients, researchers found that taking monthly or twice-monthly injections of the medication, called evolocumab, on top of statins could cut cholesterol levels by almost 60 per cent on average in patients with an underlying risk of cardiovascular disease.
Community coffee shops and automated teller machines, or ATMs, might be ideal locations for public access to automated external defibrillators (AEDs), according to new research in the American Heart Association’s journal Circulation.
Researchers advise avoiding diclofenac and limiting ibuprofen to 1200 mg per day